Vir Biotechnology Announced That Its 2020 Research Collaboration Agreement With Gsk Is Amended To Reflect That Vir Will Continue Its Ongoing Efforts To Discover, Develop And Advance Next-Generation Solutions For Covid-19 And Other Potential Coronavirus Epidemics, Independently Or With Other Partners.The Companies Will Continue To Work Together To Ensure Continued Availability Of Sotovirumab To Patients Around The World, Post-Licencing, And To Develop New Therapies For Influenza And Other Respiratory Diseases.Under The Terms Of The New Amended Agreement, Vir Retains The Sole Rights To Continue Advancing Next-Generation Solutions Arising From The Collaborative Coronavirus Vaccine And Antibody Programmes, Subject To Tiered Low- To Mid-Single Digit Royalties To Gsk. The Companies Continue To Collaborate On Sotrovimab And Vir-7832, As Well As A Portfolio Of Other Respiratory Disease Programmes.In April 2020, Gsk And Vir Entered Into A Collaboration To Research And Develop Solutions For Coronaviruses, Including Sars-Cov-2, The Virus That Causes Covid-19. The Collaboration Used Vir
